Second, the posttreatment QOL parameters were assessed only after three and six cycles of chemotherapy, therefore there might be significant undetected variations of HRQOL in between the treatment cycles.
← all excerpts
Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India.
1
—
—